clinical trial · NCT07623200
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Essential ThrombocythemiaINCA033989Best Available Treatment
brief summary
This study is being conducted to evaluate INCA033989 versus best available therapy in participants with essential thrombocythemia and a CALR mutation previously treated with cytoreductive therapy.
started
Sep 8, 2026
primary completion
Jun 15, 2029
completion
Nov 1, 2030
last updated
Aug 6, 2026
official title
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (EXCALIBUR-ET2)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol